Centene (CNC) Loses 10% on Flat Medicare Funding

We recently published 10 Big Names With Painful Declines. Centene Corp. (NYSE:CNC) was one of the worst performers on Tuesday.

Centene Corp. snapped a three-day winning streak on Tuesday, slashing 10.26 percent to finish at $41.53 apiece as investors soured on the 2027 Medicare Advantage payment updates, which saw flat funding for insurers.

According to the Centers for Medicare and Medicaid Services (CMS), net average payment is projected to increase by only 0.09 percent, far lower than the 4 to 6 percent growth as expected by analysts.

Additionally, the CMS proposed tighter risk-adjustment rules, such as excluding diagnoses made only via audio calls and some chat reviews in 2027.

The announcement dragged down share prices of several listed insurers, including Centene Corp. (NYSE:CNC), UnitedHealth Group, and Oscar Health, among others.

Centene Corp. (NYSE:CNC) is one of the leading insurers in the US, heavily dependent on government-sponsored programs such as Medicare, Medicaid, and ACA.

Centene Corp. (NYSE:CNC) is set to release the results of its earnings performance for the fourth quarter and full-year period of 2025 before market open on February 6, 2026. A conference call will be held to discuss the results.

Investors will also be closely watching out for the company’s outlook following updates to the government-sponsored programs.

While we acknowledge the potential of CNC as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.